Navigation Links
NovaLign(TM) Orthopaedics, Inc. Announces its First 510(K) Clearance From the FDA for New Intramedullary Fixation System
Date:3/25/2009

MEMPHIS, Tenn., March 25 /PRNewswire/ -- NovaLign(TM) Orthopaedics, Inc., formerly known as OsteoLign, Inc., received its first 510(k) clearance from the U.S. Food and Drug Administration to market its Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur. This regulatory clearance allows NovaLign(TM) to enter the intramedullary fracture fixation market, estimated to be $700 million in the United States for 2009. NovaLign(TM) has filed multiple U.S. and foreign patent applications related to its technology.

"Attainment of this key milestone enables the company to move forward with its plans to commercialize new products that provide innovative treatment options for long bone fracture repair," said Jeffrey G. Roberts, president and CEO of NovaLign(TM).

Extensive preclinical testing in accordance with internationally recognized testing standards and applicable FDA guidances support NovaLign's 510(k) clearance. The company plans to initiate clinical studies in Europe and the United States later this year.

Using current surgical approaches, trauma surgeons insert rigid intramedullary nails through the nearest joint. "The NovaLign(TM) extra-capsular intramedullary device allows a surgeon to repair a long bone fracture without violating the nearby joint space," said James P. Stannard, M.D., professor of surgery at the University of Alabama at Birmingham. By entering the medullary canal from outside of the joint, NovaLign's goal is to avoid damage to the surrounding tissue thereby minimizing the complications that may be experienced with traditional surgical techniques.

In July 2007, NovaLign(TM) successfully raised $10 million in its Series-B financing round from a consortium of leading venture capital companies, including Versant Ventures in Menlo Park, Calif., SV Life Sciences in Boston, Mass., and Accuitive Medical Ventures in Duluth, Ga.

About NovaLign(TM) Orthopaedics Inc.:

NovaLign(TM) (http://www.novalign.com), formerly known as OsteoLign, Inc., is an early-stage start-up company founded in 2005 within The Innovation Factory, a Duluth, Ga.-based technology incubator with a history of successfully developing medical device companies covering a broad range of medical specialties. In September 2007, the company relocated to Memphis, Tenn., and is continuing to build upon its current team of orthopaedic industry professionals.


'/>"/>
SOURCE NovaLign(TM) Orthopaedics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of DePuy Orthopaedics, Inc. Regarding Agreement with U.S. Attorneys Office
2. China Medical Technologies Announces Receipt of SFDA Quality Testing Certificate for its SPR-based Analysis System
3. The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform
4. Go Healthy Announces Receipt of Letter of Interest to Fund Distribution, Production, Packaging, Concept Stores and Bottling Facilities
5. Cord Blood America Announces Results of Shareholder Special Meeting
6. Acupuncture & Massage College Announces Ricky William's Scholarship
7. BioHorizons Announces Its 2009 Global Symposium: Bringing Together Top Thought Leaders in the Dental Implant Industry to Provide Insight on Integrating Technology into the Continuum of Care
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Maryland Performance Excellence Awards Program Announces Winners of Maryland Quality Awards
10. Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care
11. The 50 Million Pound Challenge Announces One-Millionth Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , Ginger Pigott ... LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach ... from the firm’s global Life Sciences & Medical Technology Group have been featured speakers ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to redefine ... are both engaging and easy to use. Coming off the heels of a ... today its plans to roll out new AI-powered self-service enhancements to help organizations ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has announced ... Business Report" report to their offering. ... The report also analyses the market by the following ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
Breaking Medicine Technology: